Friday, 20 Sep 2019

You are here

Biologics Are Safe When Used During Pregnancy in IBD

This is a reposting of an earlier report on RheumNow that includes additional commentary from Dr. Sunada Kane, a gastroenterologist at the Mayo Clinic who specializes in both inflammatory bowel disease (IBD) and pregnancy. 

This study analyzed Danish (2004–2012) and Swedish (2006–2012) population-based health registers to determined if TNF inhibitor (TNFi) use in patients with chronic inflammatory disease (inflammatory bowel disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, or psoriasis) resulted in a higher rate of birth defects. (Citation source http://buff.ly/1pEgwXt)

Women were exposed to TNFi treatment during early pregnancy and compared to normal controls (n = 21,549).  Birth defects were slightly more prevalent among infants born to women with chronic inflammatory disease (regardless of TNFi use), when compared to the general population (4.8% vs. 4.2%). Birth defects occurred in 6.3% of women who received anti-TNF treatment and 4.7% in women with chronic inflammatory disease not taking TNFi.

A nonsignificant trend was seen for any defect while on anti-TNF therapy (OR 1.32; 95% CI, 0.93–1.82); the OR for a cardiovascular defect was 1.60 (95% CI, 0.93–2.58), and the OR for a urinary defect was 2.22 (95% CI, 0.86–4.71).

This study is limited by a) mixing disorders (RA, PsA, IBD, AS) with highly variable risks for disease activity during pregnancy and differential rates of pregnancy related complications; and b) no adjustment for disease activity (largely because such administrative registry data does not include measures of disease activity).

In the accompanying video, Dr. Kane comments on the encouraging message from this large population based study. This is one of the largest TNFi exposed pregnancy cohorts and does not show a significantly higher risk of having children with birth defects. Some may view this slight trend for higher numbers as cautionary evidence. But, most of the evidence thus far published concur with the lack of data to indicate a serious risk for major birth defects. Larger studies are needed and would be ideal in the future.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Checkpoint Inhibitors: Who Gets Myocarditis?

The usual risk factors for myocarditis may not apply to who gets it while on immune checkpoint inhibiting cancer drugs, an FDA adverse event database suggested.

NSAIDs Mediate Cardiovascular Risk in OA

NSAIDs have been linked to an increased risk of cardiovascular disease, but does this also hold for osteoarthritis (OA) patients.

Tofacitinib Gets a New Boxed Warning for Blood Clots and Death with Higher Doses

The U.S. Food and Drug Administration has approved new warnings about an increased risk of blood clots and of death with the 10 mg twice daily dose of tofacitinib (Xeljanz, Xeljanz XR), which is used in patients with ulcerative colitis. 

EHR-Related Adverse Events Usually Involve Medications

Concerns about the unintended risks inherent in electronic health records (EHR) by analysis of EHR–related harms identified from large database of malpractice suits and claims; they found that EHR related adverse events exist, and may be associated with an severe harms and uncommonly, death.

Methotrexate Use Not Linked to Interstitial Lung Disease in RA

People with rheumatoid arthritis have a significant risk of developing interstitial lung disease (RA-ILD), yet there is often a question as to whether methotrexate (MTX) exposure can cause or worsen ILD.  A controlled cohort study suggests that MTX use is not associated with an increased risk of RA-ILD and instead, there is evidence suggesting MTX use may delay the onset of ILD.